Completed PHASE1 INTERVENTIONAL NCT00000391

A Phase I Trial of Intranasal Peptide T: Safety, Toxicity, and Pharmacokinetics in Human Immunodeficiency Virus-1 (HIV-1) Infected Patients.

Sponsor: National Institute of Mental Health (NIMH)

Interventions Peptide T

Updated 5 times since 2017 Last updated: Mar 2, 2015 Started: Jan 31, 1988 Primary completion: Jan 31, 1990

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on HIV Infections, this trial is completed. The trial is conducted by National Institute of Mental Health (NIMH) and has accumulated 5 data snapshots since 1988. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Jan 1988

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute of Mental Health (NIMH)

Data source: National Institute of Mental Health (NIMH)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States